ASCO News In Brief: Immunomedics CEA-Scan
Executive Summary
Immunomedics CEA-Scan: Diagnostic imaging agent shows 92% specificity rate in predicting which breast lesions were not cancerous in patients with inconclusive mammography findings requiring surgical biopsies. Results of the 42-patient study were reported by Dutzu Rosner, MD, State University of New York, Buffalo. In an 84-patient colorectal cancer study, CEA-Scan correctly diagnosed disease in 36 (61%) of the 59 patients who had a previous CT-negative scan. CEA-Scan became "approvable" on April 9 and the company says it is awaiting FDA approval of product labeling...